Conditions: Gastroesophageal Reflux Disease (GERD)
Keywords: GERD erosive GERD erosive esophagitis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1061
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the safety and efficacy of Rabeprazole extended release (ER) 50 mg versus Esomeprazole 40 mg for healing and symptomatic relief among subjects with erosive gastroesophageal reflux disease (GERD).

Detailed description:
This is a multicenter, randomized, double-blind, double-dummy, parallel-group study. Subjects who meet all the inclusion/exclusion criteria will be randomly assigned to 1 of 2 treatment groups, Rabeprazole ER 50 mg or Esomeprazole 40 mg for the treatment of moderate to severe erosive GERD.

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Rabeprazole sodium intervention 2: Esomeprazole
Intervention descriptions: intervention 1: Rabeprazole ER 50 mg capsule, taken orally, once daily for 4-8 weeks. intervention 2: Esomeprazole 40 mg capsule, taken orally, once daily for 4-8 weeks.

Protocol document: